TTFields therapy promotes survival benefit in unresectable pancreatic cancer

Tumour Treating Fields (TTFields) therapy has demonstrated a significant survival benefit when used in combination with gemcitabine and nab-paclitaxel as first-line treatment for participants with unresectable locally advanced pancreatic cancer, according to findings from the phase 3 PANOVA-3 trial. The TTFields therapy uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division and inhibit tumour growth. It is already approved for glioblastoma and mesothelioma and is being studied across multiple solid tumour types. PANOVA-3 (NCT03377491), presented by Dr Vincent Picozzi (Virginia Mason Medical Centre, Seattle, WA, USA), enrolled 571 participants, representing the largest randomised trial to date evaluating TTFields therapy in this setting [1]. Participants with newly diagnosed, locally advanced pancreatic cancer were randomly assigned to receive s...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025